|Bid||3.7200 x 3100|
|Ask||10.0000 x 4000|
|Day's Range||3.4900 - 3.8600|
|52 Week Range||2.3400 - 9.8500|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
BERKELEY, Calif., March 07, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Aduro management is scheduled to present at the following investor conferences:.
Aduro BioTech, Inc.'s (NASDAQ:ADRO) latest earnings update in December 2018 signalled company earnings became less negative compared to the previous year's level as a result of recent tailwinds Below, I'veRead More...
BERKELEY, Calif., Feb. 28, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that three abstracts will be presented at the American Association for Cancer Research.
BERKELEY, Calif., Feb. 27, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018.
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
BERKELEY, Calif., Feb. 21, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
Aduro Biotech, Inc. (ADRO) today announced the appointment of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals, to its Board of Directors effective February 19, 2019. “As we advance our first-in-class STING and APRIL product candidates through the clinic, David’s strategic approach to drug development in oncology coupled with his exceptional leadership skills will be tremendously valuable and we look forward to his guidance and contributions,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “On behalf of the Board, shareholders and employees, I would also like to thank and recognize Frank for his support over the last nine years, which helped to shape Aduro and its core technologies from our founding to where we are today.
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
Aduro Biotech, Inc. (ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes (STING) pathway activator, in combination with YERVOY® (ipilimumab), an approved anti-CTLA-4 antibody for the treatment of relapsed and refractory melanoma. The multicenter trial (see www.clinicaltrials.gov, identifier: NCT02675439), which is part of an ongoing research and development collaboration with Novartis, will enroll advanced melanoma patients who have relapsed after or are refractory to treatment with anti-PD-1 antibodies, nivolumab or pembrolizumab. “We are pleased to initiate this study evaluating ADU-S100 with ipilimumab in a homogeneous patient population.